Literature DB >> 21078718

Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time.

Dominique Ibañez1, Dafna D Gladman, Zahi Touma, Mandana Nikpour, Murray B Urowitz.   

Abstract

OBJECTIVE: adjusted mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; AMS) measures lupus disease activity over time. Our aim was to determine optimal visit frequency for calculating AMS.
METHODS: patients followed monthly for 12 consecutive visits were included. AMS was calculated using all of the SLEDAI 2000 (AMS(GOLD) using all 12 visits), only quarterly visits (AMS(3), using visits 3 months apart), semiannual visits (AMS(6), using first, middle, and last visits only), and annual visits (AMS(12), using only the first and last visits). Comparisons of AMS(3), AMS(6), and AMS(12) with AMS(GOLD) are made using descriptive statistics.
RESULTS: seventy-eight patients were included (92% women, mean age at SLE diagnosis 30.1 yrs and at study start 46.2 yrs). The mean (SD) AMS(GOLD) for the entire year was 2.05 (1.66), for AMS(3) 1.99 (1.65), for AMS(6) 2.12 (1.87), and for AMS(12) 2.08 (1.83). Mean (SD) of the absolute differences with AMS(GOLD): for AMS(3) 0.29 (0.33), for AMS(6) 0.45 (0.59), and for AMS(12) 0.61 (0.58). Differences that were < 0.5 were considered minimal while those ≥ 1 were deemed important. Comparing AMS(GOLD) to AMS(3), 82% of the differences were minimal and 3% were important. When comparing to AMS(6), 68% were minimal and 10% were important, while comparing to AMS(12), 50% were minimal and 21% were important.
CONCLUSION: usual clinic visits occurring quarterly offer a good estimation of disease activity over a 1-year period and are preferred over semiannual and annual visits.

Entities:  

Mesh:

Year:  2010        PMID: 21078718     DOI: 10.3899/jrheum.100575

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus.

Authors:  Huanhuan Ma; Jing Dong; Liqin Wang; Lei Zhao; Lin Pan
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth.

Authors:  Joyce C Chang; David S Mandell; Andrea M Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-08-16       Impact factor: 4.794

3.  Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study.

Authors:  Linda L D Zhong; Zhao Xiang Bian; Jun Hua Gu; Xin Zhou; Yu Tian; Jian Chun Mao; Xiang Jun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

4.  Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.

Authors:  Anselm Mak; Nien Yee Kow; Herbert Schwarz; Lingli Gong; Sen Hee Tay; Lieng Hsi Ling
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

5.  Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus.

Authors:  Warren Raymond; Gro Eilertsen; Johannes Nossent
Journal:  J Immunol Res       Date:  2018-12-30       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.